- Dr. Kim Discusses PD-L1 as a Biomarker in Lung Cancer ( Download)
- Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer ( Download)
- Dr. Kim on the Importance of Biomarker Testing for Lung Cancer ( Download)
- PD-L1 as a Biomarker in Squamous Non-Small Cell Lung Cancer ( Download)
- Dr. Kim on Clinical Trial Eligibility Criteria in Lung Cancer ( Download)
- Edward Kim, MD, provides insight on how to use the PD-L1 biomarker to direct therapy ( Download)
- Edward Kim, MD, on anti-PD-L1/PD-1 combination therapies in treatment of lung cancer ( Download)
- PD-L1 Expression in NSCLC ( Download)
- Dr. Kim Addresses Concerns About Hyperprogression in NSCLC ( Download)
- Studies in Anti-PD-L1 Monotherapy for NSCLC - Lung Cancer OncTalk 2022 ( Download)
- How Does PD-L1 Score Affect Treatment Options - Lung Cancer OncTalk 2022 ( Download)
- Emerging Biomarkers in Lung Cancer ( Download)
- Novel therapy for Lung Cancer: From targeted therapy to immuno-therapy and back again! ( Download)
- The Significance of Biomarker Testing in Patient Identification ( Download)
- Webinar - PD-1/PD-L1 Inhibitors: The First Wave of Immuno-Oncology ( Download)
